Ameriprise’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-22,470
| Closed | -$20.8K | – | 4131 |
|
|
2025
Q1 | $20.8K | Hold |
22,470
| – | – | ﹤0.01% | 3982 |
|
|
2024
Q4 | $19.3K | Hold |
22,470
| – | – | ﹤0.01% | 4053 |
|
|
2024
Q3 | $37.3K | Hold |
22,470
| – | – | ﹤0.01% | 3894 |
|
|
2024
Q2 | $36.2K | Hold |
22,470
| – | – | ﹤0.01% | 3828 |
|
|
2024
Q1 | $51.5K | Sell |
22,470
-9
| -0% | -$21 | ﹤0.01% | 3812 |
|
|
2023
Q4 | $50.6K | Sell |
22,479
-17
| -0.1% | -$41 | ﹤0.01% | 3853 |
|
|
2023
Q3 | $67.9K | Buy |
22,496
+16
| +0.1% | +$61 | ﹤0.01% | 3823 |
|
|
2023
Q2 | $92.6K | Hold |
22,480
| – | – | ﹤0.01% | 3824 |
|
|
2023
Q1 | $84.3K | Hold |
22,480
| – | – | ﹤0.01% | 3844 |
|
|
2022
Q4 | $126K | Sell |
22,480
-10
| -0% | -$59 | ﹤0.01% | 3782 |
|
|
2022
Q3 | $149K | Sell |
22,490
-10
| -0% | -$81 | ﹤0.01% | 3755 |
|
|
2022
Q2 | $224K | Buy |
22,500
+22,289
| +10,564% | +$213K | ﹤0.01% | 3658 |
|
|
2022
Q1 | $4K | Sell |
211
-117,114
| -100% | -$1.84M | ﹤0.01% | 3928 |
|
|
2021
Q4 | $2.08M | Buy |
117,325
+19,072
| +19% | +$572K | ﹤0.01% | 2939 |
|
|
2021
Q3 | $3.64M | Sell |
98,253
-21,151
| -18% | -$939K | ﹤0.01% | 2594 |
|
|
2021
Q2 | $7.1M | Buy |
119,404
+24,080
| +25% | +$1.46M | ﹤0.01% | 2194 |
|
|
2021
Q1 | $6.39M | Buy |
95,324
+3,254
| +4% | +$255K | ﹤0.01% | 2237 |
|
|
2020
Q4 | $5.57M | Buy |
92,070
+9,592
| +12% | +$655K | ﹤0.01% | 2197 |
|
|
2020
Q3 | $6.52M | Sell |
82,478
-10,025
| -11% | -$799K | ﹤0.01% | 1894 |
|
|
2020
Q2 | $5.78M | Sell |
92,503
-4,235
| -4% | -$247K | ﹤0.01% | 1958 |
|
|
2020
Q1 | $5.13M | Buy |
96,738
+27,770
| +40% | +$2.75M | ﹤0.01% | 1893 |
|
|
2019
Q4 | $8.35M | Buy |
68,968
+21,031
| +44% | +$3.02M | ﹤0.01% | 1891 |
|
|
2019
Q3 | $8.7M | Buy |
47,937
+14,248
| +42% | +$2.01M | ﹤0.01% | 1809 |
|
|
2019
Q2 | $4.38M | Buy |
33,689
+3,582
| +12% | +$642K | ﹤0.01% | 2320 |
|
|
2019
Q1 | $7.33M | Sell |
30,107
-1,872
| -6% | -$495K | ﹤0.01% | 1945 |
|
|
2018
Q4 | $6.09M | Buy |
31,979
+18,670
| +140% | +$4.55M | ﹤0.01% | 1987 |
|
|
2018
Q3 | $4.37M | Buy |
13,309
+3,901
| +41% | +$1.2M | ﹤0.01% | 2422 |
|
|
2018
Q2 | $2.94M | Sell |
9,408
-2,493
| -21% | -$762K | ﹤0.01% | 2561 |
|
|
2018
Q1 | $2.9M | Buy |
+11,901
| New | +$3.34M | ﹤0.01% | 2526 |
|
|
2016
Q3 | – | Sell |
-4,493
| Closed | -$1.91M | – | 3839 |
|
|
2016
Q2 | $1.91M | Sell |
4,493
-351
| -7% | -$145K | ﹤0.01% | 2551 |
|
|
2016
Q1 | $1.55M | Buy |
4,844
+817
| +20% | +$279K | ﹤0.01% | 2645 |
|
|
2015
Q4 | $2.09M | Buy |
+4,027
| New | +$1.49M | ﹤0.01% | 2578 |
|
|
2014
Q4 | – | Sell |
-1
| Closed | – | – | 4364 |
|
|
2014
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 5896 |
|
|
2014
Q2 | $0 | Sell |
1
-3,323
| -100% | -$739K | ﹤0.01% | 5656 |
|
|
2014
Q1 | $1.05M | Buy |
3,324
+3,323
| +332,300% | +$1.06M | ﹤0.01% | 2712 |
|
|
2013
Q4 | $0 | Sell |
1
-97
| -99% | -$21.2K | ﹤0.01% | 5411 |
|
|
2013
Q3 | $14K | Sell |
98
-6
| -6% | -$725 | ﹤0.01% | 4663 |
|
|
2013
Q2 | $16K | Buy |
+104
| New | +$14.2K | ﹤0.01% | 4438 |
|
Other funds holding TXMD
RCMNY
CC
TC
ACM
BCM
Ameriprise's TXMD Position: Q2 2025 in Review
Ameriprise sold out of TherapeuticsMD (TXMD) in Q2 2025, closing a stake of 22,470 shares — an estimated $20.8K sold.
Ameriprise first reported a position in TXMD in Q2 2013 and held it in 38 quarters. The position peaked at $8.7M in Q3 2019. 42 funds tracked by Wall St. Rank hold TXMD as of Q2 2025.
- Ameriprise reported no remaining TherapeuticsMD position as of Q2 2025 after selling out during the quarter.
- Ameriprise sold 22,470 TherapeuticsMD shares in Q2 2025, an estimated $20.8K.
- Ameriprise first reported a position in TherapeuticsMD in Q2 2013 and held it in 38 quarters.
- Ameriprise's TherapeuticsMD position peaked at $8.7M in Q3 2019.
- 42 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2025.
Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.